What actually changes
Menopause completes, and bone loss accelerates with it
The median age at final menstrual period is around 51. Bone mineral density falls fastest in the few years either side of it, which makes this a window where resistance and impact loading, adequate protein, and a decision about hormone therapy all have more leverage than they will later.
Cardiovascular risk scores start to discriminate
Ten-year risk calculators are close to useless at 35 and genuinely informative at 55, because the event rate is finally high enough for the arithmetic to separate people. A calculated risk here should change what you do, not just what you know.
Muscle loss becomes visible rather than statistical
Sarcopenia accelerates through this decade. Grip strength and a sit-to-stand test are crude, free, and predict function decades out better than most things a lab can measure.
Interventions graded in this group
Nothing in our catalogue carries a grade whose population names this group specifically. That is worth stating plainly rather than filling the space: what we have is evidence in mixed populations, and applying it here is an assumption.
Browse every graded intervention instead
Most longevity interventions with any trial evidence were tested in people around this age or older, which means the evidence base is at its strongest here — and still mostly short, small trials on biomarkers rather than outcomes.
Which tests matter, and when
This is the decade to move from baseline panels to risk stratification: lipids with ApoB, a calculated cardiovascular risk, and — where it would change a decision — coronary calcium scoring or bone density. Each of those should be ordered because a decision hangs on it, not for completeness.
No marker in our catalogue has a reference range sliced specifically for this group, so the general ranges apply. See the full range table.